Novel indolo[3,2-6]quinolines (l d-g), introduced at the 7-position with an N- glycosylamino group, were prepared and their antitumor activities against leukemia P388 in mice were examined. The N-Galactopyranosylamino derivative (le) was a much more potent anti-leukemia compound (optimal dose = 25 mg/kg, T/C > 333%, cure 5/6) than lead compound la.
- 2-6]quinoline glycosylation antitumor activity intercalation P388 leukemia
ASJC Scopus subject areas
- Drug Discovery